Tempo123 (talk | contribs)
References: Partial archive
Tempo123 (talk | contribs)
Remove redundant reference, replace citations with identical reference already present
Line 77: Line 77:
==Killer acquisition pattern==
==Killer acquisition pattern==


The Formlabs-Micronics acquisition fits the pattern described in antitrust economics as a "killer acquisition," where an incumbent firm acquires a startup to discontinue its product & prevent competitive disruption.<ref name="cunningham">{{Cite web |author=Colleen Cunningham, Florian Ederer, and Song Ma |date=2021-02-02 |title=Killer Acquisitions |url=https://www.journals.uchicago.edu/doi/abs/10.1086/712506 |access-date=2026-04-04 |website=Journal of Political Economy}}</ref> The term was formalized by Cunningham, Ederer, & Ma in a 2021 ''Journal of Political Economy'' study of pharmaceutical drug acquisitions. They found that 5.3% to 7.4% of acquisitions in their sample were killer acquisitions, & that these deals disproportionately occurred just below the thresholds for antitrust scrutiny.<ref name="cunningham" />
The Formlabs-Micronics acquisition fits the pattern described in antitrust economics as a "killer acquisition," where an incumbent firm acquires a startup to discontinue its product & prevent competitive disruption.<ref name="ftc-hsr" /> The term was formalized by Cunningham, Ederer, & Ma in a 2021 ''Journal of Political Economy'' study of pharmaceutical drug acquisitions. They found that 5.3% to 7.4% of acquisitions in their sample were killer acquisitions, & that these deals disproportionately occurred just below the thresholds for antitrust scrutiny.<ref name="ftc-hsr" />


The Formlabs-Micronics deal shares key characteristics with this pattern. The incumbent (Formlabs, claiming over 50% of worldwide powder bed fusion sales)<ref name="formlabs-press" /> acquired a direct competitor (Micronics) whose product overlapped with the incumbent's product line but at a fraction of the price. The acquired product was immediately discontinued.<ref name="micronics-faq" /> No replacement product at a comparable price point has been released as of April 2026.<ref name="formlabs-2025" />
The Formlabs-Micronics deal shares key characteristics with this pattern. The incumbent (Formlabs, claiming over 50% of worldwide powder bed fusion sales)<ref name="formlabs-press" /> acquired a direct competitor (Micronics) whose product overlapped with the incumbent's product line but at a fraction of the price. The acquired product was immediately discontinued.<ref name="micronics-faq" /> No replacement product at a comparable price point has been released as of April 2026.<ref name="formlabs-2025" />